Published in CA Cancer J Clin on January 22, 2007
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis (2010) 2.13
Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis (2010) 2.03
Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med (2010) 1.74
Modeling cervical cancer prevention in developed countries. Vaccine (2008) 1.61
Prognostic value of histopathology and trends in cervical cancer: a SEER population study. BMC Cancer (2007) 1.48
Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol (2009) 1.45
Genital warts: a comprehensive review. J Clin Aesthet Dermatol (2012) 1.40
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med (2009) 1.29
Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. Br J Cancer (2008) 1.27
Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol (2009) 1.16
Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med (2008) 1.15
Human papillomavirus vaccine use among adolescent girls and young adult women: an analysis of the 2007 California Health Interview Survey. J Womens Health (Larchmt) (2012) 1.15
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J (2015) 1.13
Feasibility of self-sampling and human papillomavirus testing for cervical cancer screening in First Nation women from Northwest Ontario, Canada: a pilot study. BMJ Open (2011) 1.12
Use of human papillomavirus vaccines among young adult women in the United States: an analysis of the 2008 National Health Interview Survey. Cancer (2011) 1.12
Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine (2011) 1.10
Update on prevention and screening of cervical cancer. World J Clin Oncol (2014) 1.07
Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am (2007) 1.07
Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol (2008) 1.05
The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One (2014) 0.99
Cancer immunotherapy: are we there yet? Exp Hematol Oncol (2013) 0.98
A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study. PLoS One (2013) 0.97
Metformin impairs the growth of liver kinase B1-intact cervical cancer cells. Gynecol Oncol (2012) 0.97
The impact of human papillomavirus vaccination on cervical cancer prevention efforts. Gynecol Oncol (2009) 0.95
Risk factors for cervical cancer in criminal justice settings. J Womens Health (Larchmt) (2011) 0.92
Primary care providers human papillomavirus vaccine recommendations for the medically underserved: a pilot study in U.S. Federally Qualified Health Centers. Vaccine (2014) 0.91
Cervical cancer in India and HPV vaccination. Indian J Med Paediatr Oncol (2012) 0.89
A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag (2008) 0.89
Human papillomavirus vaccination in survivors of childhood cancer. Cancer (2009) 0.89
Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Rev Obstet Gynecol (2008) 0.89
Understanding how mothers of adolescent girls obtain information about the human papillomavirus vaccine: associations between mothers' health beliefs, information seeking, and vaccination intentions in an ethnically diverse sample. J Health Psychol (2012) 0.88
The future of vaccines for cervical cancer. Gynecol Oncol (2008) 0.87
Prevalence of HPV Infection and High Risk HPV Genotypes (16, 18), among Monogamous and Polygamous Women, In Zabol, Iran. Iran J Public Health (2011) 0.86
Predicting pediatricians' communication with parents about the human papillomavirus (hpv) vaccine: an application of the theory of reasoned action. Health Commun (2011) 0.85
Developing a Tablet-Based Self-Persuasion Intervention Promoting Adolescent HPV Vaccination: Protocol for a Three-Stage Mixed-Methods Study. JMIR Res Protoc (2016) 0.84
How does public policy impact cervical screening and vaccination strategies? Gynecol Oncol (2010) 0.83
Financial strain and cancer risk behaviors among African Americans. Cancer Epidemiol Biomarkers Prev (2014) 0.83
Women's intentions to receive cervical cancer screening with primary human papillomavirus testing. Int J Cancer (2013) 0.82
Viral carcinogenesis: factors inducing DNA damage and virus integration. Cancers (Basel) (2014) 0.82
Ginsenoside‑Rg5 induces apoptosis and DNA damage in human cervical cancer cells. Mol Med Rep (2014) 0.81
Human papillomavirus vaccination: a case for mandatory immunization? J Pediatr Pharmacol Ther (2008) 0.80
Insurance continuity and human papillomavirus vaccine uptake in Oregon and California federally qualified health centers. Am J Public Health (2014) 0.80
Clinical significance of human papillomavirus genotyping. J Gynecol Oncol (2016) 0.80
Human papillomavirus disease and vaccines in adolescents. Adolesc Med State Art Rev (2010) 0.80
The Digital Distribution of Public Health News Surrounding the Human Papillomavirus Vaccination: A Longitudinal Infodemiology Study. JMIR Public Health Surveill (2015) 0.80
Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Med Decis Making (2012) 0.79
Human papilloma virus and cervical preinvasive disease. J Med Life (2010) 0.78
Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer. Cancer Prev Res (Phila) (2013) 0.78
Highly Sensitive Detection and Genotyping of HPV by PCR Multiplex and Luminex Technology in a Cohort of Colombian Women with Abnormal Cytology. Open Virol J (2011) 0.77
A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus. Hum Vaccin Immunother (2013) 0.77
Cervical pap screening cytological abnormalities among HIV-infected adolescents in the LEGACY cohort. J Pediatr Adolesc Gynecol (2011) 0.77
HPV genotypes in paraffin sections of non-cervical squamous cell carcinoma in Qingdao of China. Oncol Lett (2013) 0.77
Preventing Hepatitis B-induced Liver Cancer: Implications for Eliminating Health Disparities. J Health Dispar Res Pract (2010) 0.77
Cancer prevention in HIV-infected populations. Semin Oncol (2015) 0.77
Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health (2012) 0.76
Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer. Pediatr Blood Cancer (2015) 0.76
Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world? Ann Med Health Sci Res (2013) 0.76
Management strategies and cost effectiveness in the prevention of cervical cancer. Clinicoecon Outcomes Res (2009) 0.75
Human papillomavirus vaccine acceptance among young men in Bangalore, India. Int J Dermatol (2014) 0.75
Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer. J Cancer Surviv (2015) 0.75
Opportunities and Challenges of Adolescent and Adult Vaccination Administration Within Pharmacies in the United States. Biomed Inform Insights (2017) 0.75
Variation in Human Papillomavirus Vaccine Uptake and Acceptability Between Female and Male Adolescents and Their Caregivers. J Community Health (2016) 0.75
Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination. Sex Transm Dis (2016) 0.75
Using qualitative methods to develop a contextually tailored instrument: Lessons learned. Asia Pac J Oncol Nurs (2016) 0.75
Projecting productivity losses for cancer-related mortality 2011 - 2030. BMC Cancer (2016) 0.75
Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology. Hum Vaccin Immunother (2016) 0.75
Cervical cytology screening among low-income, minority adolescents in New York City following the 2009 ACOG guidelines. Prev Med (2014) 0.75
A paper-based immunoassay to determine HPV vaccination status at the point-of-care. Vaccine (2016) 0.75
Evaluation of 3D-CPA, HR-HPV, and TCT joint detection on cervical disease screening. Oncol Lett (2016) 0.75
Kaempferia parviflora Extract Exhibits Anti-cancer Activity against HeLa Cervical Cancer Cells. Front Pharmacol (2017) 0.75
Male reproductive health challenges: appraisal of wives coping strategies. Reprod Health (2017) 0.75
[Anal HPV infections]. Wien Klin Wochenschr (2008) 0.75
Risk of cancer in patients with genital warts: A nationwide, population-based cohort study in Taiwan. PLoS One (2017) 0.75
Hyaluronic acid binding protein 1 overexpression is an indicator for disease-free survival in cervical cancer. Int J Clin Oncol (2016) 0.75
Global health 2035: a world converging within a generation. Lancet (2013) 16.85
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin (2008) 12.90
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res (2006) 10.45
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA (2002) 6.55
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin (2002) 5.56
Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet (2003) 5.40
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology (2011) 5.17
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen (2010) 4.72
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Worldwide variations in colorectal cancer. CA Cancer J Clin (2009) 4.71
American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin (2006) 4.69
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
High-throughput SNP genotyping on universal bead arrays. Mutat Res (2005) 3.78
Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med (2007) 3.77
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67
Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin (2006) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. Chest (2004) 3.55
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Decoding randomly ordered DNA arrays. Genome Res (2004) 3.49
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med (2003) 3.26
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin (2006) 3.21
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis (2012) 3.19
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med (2005) 3.01
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis. Ann Intern Med (2004) 2.95
The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol (2007) 2.91
Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation (2004) 2.91
The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer (2002) 2.85
The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg (2005) 2.83
Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc (2007) 2.82
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Counterpoint: Overdiagnosis in breast cancer screening. J Am Coll Radiol (2014) 2.75
Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol (2009) 2.74
Measuring the significance of field validation in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology: how good are the experts? Arch Pathol Lab Med (2005) 2.69
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst (2006) 2.67
Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol (2010) 2.65